Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Accured Expenses (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Change in Accured Expenses for 4 consecutive years, with -$2.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses fell 548.7% year-over-year to -$2.2 million, compared with a TTM value of -$12.4 million through Sep 2025, down 285.36%, and an annual FY2024 reading of -$12.5 million, down 213.02% over the prior year.
  • Change in Accured Expenses was -$2.2 million for Q3 2025 at Atara Biotherapeutics, up from -$4.9 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $10.5 million in Q4 2023 and bottomed at -$8.8 million in Q1 2022.
  • Average Change in Accured Expenses over 4 years is -$203333.3, with a median of -$64000.0 recorded in 2022.
  • Peak annual rise in Change in Accured Expenses hit 343.32% in 2023, while the deepest fall reached 6921.88% in 2023.
  • Year by year, Change in Accured Expenses stood at $9.6 million in 2022, then increased by 8.79% to $10.5 million in 2023, then crashed by 183.7% to -$8.8 million in 2024, then skyrocketed by 74.42% to -$2.2 million in 2025.
  • Business Quant data shows Change in Accured Expenses for ATRA at -$2.2 million in Q3 2025, -$4.9 million in Q2 2025, and $3.5 million in Q1 2025.